Inspira Technologies OXY B.H.N. (NASDAQ:IINN) and Sartorius (OTCMKTS:SARTF) Financial Contrast

Inspira Technologies OXY B.H.N. (NASDAQ:IINN) and Sartorius (OTCMKTS:SARTF) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, institutional ownership, earnings, profitability and dividends.

Insider & Institutional Ownership

12.7% of Inspira Technologies OXY B.H.N. shares are owned by institutional investors. 29.4% of Inspira Technologies OXY B.H.N. shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Inspira Technologies OXY B.H.N. and Sartorius’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Inspira Technologies OXY B.H.N.	N/A	N/A	N/A
Sartorius	3.82%	8.19%	3.15%

Risk & Volatility

Inspira Technologies OXY B.H.N. has a beta of 2.25, indicating that its share price is 125% more volatile than the S&P 500. Comparatively, Sartorius has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for Inspira Technologies OXY B.H.N. and Sartorius, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inspira Technologies OXY B.H.N.	1	0	1	0	2.00
Sartorius	0	1	0	1	3.00

Inspira Technologies OXY B.H.N. presently has a consensus target price of $2.00, indicating a potential upside of 180.43%. Given Inspira Technologies OXY B.H.N.’s higher probable upside, analysts plainly believe Inspira Technologies OXY B.H.N. is more favorable than Sartorius.

Earnings and Valuation

This table compares Inspira Technologies OXY B.H.N. and Sartorius”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inspira Technologies OXY B.H.N.	N/A	N/A	-$11.05 million	N/A	N/A
Sartorius	$3.66 billion	2.12	$90.90 million	$2.15	105.27

Sartorius has higher revenue and earnings than Inspira Technologies OXY B.H.N..

Summary

Sartorius beats Inspira Technologies OXY B.H.N. on 7 of the 12 factors compared between the two stocks.

About Inspira Technologies OXY B.H.N.

Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation for the treatment of acute respiratory failure. Its lead product is the augmented respiration technology system, a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels. The company was formerly known as Insense Medical Ltd. and changed its name to Inspira Technologies Oxy B.H.N. Ltd. in July 2020. Inspira Technologies Oxy B.H.N. Ltd. was incorporated in 2018 and is headquartered in Ra'annana, Israel.

About Sartorius

Sartorius Aktiengesellschaft provides bioprocess solutions and lab products and services in the United States and internationally. The company offers multi-parallel, benchtop, single-use, stainless steel, cell culture, rocking motion, and microbial bioreactors, and software apps for bioreactors and cell culture shake flask; fermenters; cell culture media products; cellcelector flex, incubator flowbox, nanowell arrays, and capillaries and tips; fluid management products; microbiology products; and Ultrafiltration membrane filters, glass and quartz microfiber filters, clarification, syringeless and in-line filters, lab chromatography, and filters and blotting papers. It also provides live-cell analysis systems, reagents and consumables, support and services, and live-cell imaging and analysis software; contract manufacturing and integration, membranes and devices, weigh cells, and data analytics, as well as connectivity, and pipetting and dispensing modules; electronic and mechanical pipettes, pipette tips, bottle-top dispensers, and pipette controllers and accessories; process automation platform and software, sensors and analyzers, biomolecule analysis tools, and data analytics software; chromatography consumables, columns, and systems; and biolayer interferometry products. In addition, the company offers water purification systems; surface plasmon resonance; lab balances, pipette calibration, mass comparators and metrology, moisture analyzers, equipment manufacturer cells, weights and weight sets, paint mixing solutions, and weighing accessories; and process filtration. Further, the company provides bioprocess consulting and engineering, biologics testing, media and process, instrument, octet service and support, and validation services. It serves the life science research, biopharmaceutical manufacturing, pharmaceutical quality control, cell and gene therapy, and applied industries. Sartorius Aktiengesellschaft was founded in 1870 and is headquartered in Göttingen, Germany.